Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Microsoft (MSFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Microsoft — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Microsoft trades at $382.26 (market cap $2.89T). The key difference: Microsoft is far larger — about 643.7× ACADIA Pharmaceuticals Inc.'s market cap, and Microsoft pays a 0.94% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MSFT | |
|---|---|---|
Market Cap | $4.49B | $2.89T |
Sector | Health | Technology |
52-Week High | $28.06 | $542.07 |
52-Week Low | $20.06 | $352.83 |
Enterprise Value | $3.69B | $2.87T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Microsoft trades at $382.74, down 1.03% today, with strong fundamentals including 36.14% net margin and consistent earnings beats. The stock shows bullish technical signals despite mixed indicators, with support at $379. Analyst consensus remains overwhelmingly positive with 80% buy ratings and a $550.43 price target. Recent news highlights Microsoft's AI leadership and cloud growth potential.
Outlook remains positive given Microsoft's dominant market position, AI integration across products, and robust financials. Risks include increased capital expenditure concerns and competitive pressures. The stock offers growth potential through Azure expansion and Copilot adoption, though investors should monitor execution on AI investments and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
